ライフサイエンスコーパス: medroxyprogesterone acetate

1 te the concurrent administration of low dose medroxyprogesterone acetate.

2 h 8-bromo-cyclic adenosine monophosphate and medroxyprogesterone acetate.

3 uterus in the trial of these estrogens plus medroxyprogesterone acetate.

4 nsdermal estradiol, 100 micro g/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10

5 njugated equine estrogen 0.625 mg a day plus medroxyprogesterone acetate 2.5 mg a day increased the r

6 ted equine estrogens 0.625 mg (combined with medroxyprogesterone acetate 2.5 mg daily in five women w

7 rogen (0.625 mg/d), estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/d), or placebo.

8 h a uterus received estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day) or placebo.

9 l women, either alone or in combination with medroxyprogesterone acetate (2.5 mg daily) for one month

10 ted equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo.

11 ted equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo.

12 ed equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily or to placebo

13 o daily conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg) or placebo and docu

14 quine estrogens (0.625 mg/d [estrogen]) plus medroxyprogesterone acetate (2.5 mg/d [progestin]) (E +

15 onjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) if they had a ute

16 y conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate); 2) 20 mg lovastatin/day an

17 ne estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily; or 5) placebo

18 Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, daily in one tablet

19 conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (

20 Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in one tablet (n =

21 (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d); or placebo.

22 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n =

23 conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n =

24 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or identical plac

25 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill.

26 onjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo.

27 gated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45)

28 gated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days.

29 d serious adverse reactions to intramuscular medroxyprogesterone acetate, a drug that contains polyet

30 Exposure of xenografts to medroxyprogesterone acetate, a synthetic progestin used

31 In women using depot medroxyprogesterone acetate, adjusted pregnancy incidenc

32 Neither estrogen alone nor estrogen plus medroxyprogesterone acetate affected the progression of

33 w a progestational contraceptive drug (depot medroxyprogesterone acetate) affects food intake, restin

34 Conjugated equine estrogen plus medroxyprogesterone acetate also increased the overall r

35 a-dihydrotestosterone, 17 beta-estradiol, or medroxyprogesterone acetate, also inhibited LNCaP 104-R2

36 gnal transduction, was also synergistic with medroxyprogesterone acetate and E2, but induced signific

37 Medroxyprogesterone acetate and estradiol (E2) had no ef

38 norethynodrel), hormone replacement therapy (medroxyprogesterone acetate), and high-dose progestin tr

39 eeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2.

40 in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively.

41 idence interval [CI], 1.7-12.2), use of depo-medroxyprogesterone acetate (aOR, 3.2; 95% CI, 1.3-7.7),

42 o++ +[3,4-f] quinoline) was more potent than medroxyprogesterone acetate at counterpoising the effect

43 deployed drug combination of bezafibrate and medroxyprogesterone acetate (BaP) has shown anti-leukaem

44 ural progesterone and the clinical progestin medroxyprogesterone acetate block estrogen neuroprotecti

45 Although medroxyprogesterone acetate but not E(2) increased Ang-1

46 ule) alone or administered sequentially with medroxyprogesterone acetate can slow the progression of

47 d a hysterectomy were randomized to CEE plus medroxyprogesterone acetate (CEE + MPA) or placebo.

48 nt with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increa

49 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group rece

50 625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily, or placebo.

51 deployed drug combination of bezafibrate and medroxyprogesterone acetate (designated BaP) has potent

52 le (control), estradiol (E2) with or without medroxyprogesterone acetate, dexamethasone (Dex), or Org

53 measurements indicated that the addition of medroxyprogesterone acetate did not affect MCP-1 output,

54 cycle affected energy intake and REE, depot medroxyprogesterone acetate did not alter energy intake

55 nt with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall r

56 combined oral contraceptives (COCs) or depot medroxyprogesterone acetate (DMPA) (15/group).

57 Increasing evidence suggests depot medroxyprogesterone acetate (DMPA) and intravaginal prac

58 Depot medroxyprogesterone acetate (DMPA) and vaginal dysbiosis

59 rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) are unknown.

60 he use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) at the time of HIV-1

61 Women who used depo medroxyprogesterone acetate (DMPA) had an increased inci

62 The injectable hormonal contraceptive depo-medroxyprogesterone acetate (DMPA) has been associated w

63 Depot medroxyprogesterone acetate (DMPA) has been linked to hu

64 of the progesterone (Pg) birth control depot medroxyprogesterone acetate (DMPA) increases a woman's r

65 Depot medroxyprogesterone acetate (DMPA) inhibits proliferatio

66 y investigates the association between depot medroxyprogesterone acetate (DMPA) injectable contracept

67 Depo-medroxyprogesterone acetate (DMPA) is an injectable cont

68 Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bo

69 The contraceptive depot-medroxyprogesterone acetate (DMPA) likewise promotes vag

70 The hormonal contraceptive depot medroxyprogesterone acetate (DMPA) may be associated wit

71 Studies that assessed the use of depot-medroxyprogesterone acetate (DMPA) or non-specified inje

72 es (COCs) or the injectable progestins depot-medroxyprogesterone acetate (DMPA) or norethisterone ena

73 Reliable contraceptives (injectable Depot Medroxyprogesterone Acetate (DMPA), implant, pills, and

74 The injectable contraceptive, depot medroxyprogesterone acetate (DMPA), is associated with c

75 ceptive currently available in the US, depot medroxyprogesterone acetate (DMPA), is limited by signif

76 ice were treated with vehicle, 2 mg of depot medroxyprogesterone acetate (DMPA), or 10 mg of DMPA eve

77 dress this discrepancy, we developed a Depot medroxyprogesterone acetate (DMPA)-treated cotton rat Si

78 roxil fumarate (TDF) and intramuscular depot medroxyprogesterone acetate (DMPA-IM) are independently

79 the impact of initiating intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper-IUD, and t

80 the effect of injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel im

81 rial randomized women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel im

82 genous hormones, such as intramuscular depot medroxyprogesterone acetate (DMPA-IM), may alter the com

83 acquisition with use of intramuscular depot medroxyprogesterone acetate (DMPA-IM).

84 evels in HIV-uninfected women who used depot medroxyprogesterone acetate (DMPA; n = 32), the levonorg

85 patch, contraceptive vaginal ring, and depot medroxyprogesterone acetate [DMPA] injection) in the ove

86 state (pregnancy or pretreatment with depot medroxyprogesterone acetate [DMPA]) even in Ifnar1(-/-)

87 h vehicle control, estradiol (E(2)), or with medroxyprogesterone acetate +/- E(2) under hypoxic and n

88 gamma (IFN-gamma) reversed these effects and medroxyprogesterone acetate elicited further reversal.

89 eta-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group).

90 conjugated equine estrogens, with or without medroxyprogesterone acetate, focusing on health benefits

91 y with oral conjugated equine estrogens plus medroxyprogesterone acetate for postmenopausal women or

92 conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a

93 CEE with or without medroxyprogesterone acetate, given to women age 65 years

94 ther alone or with sequentially administered medroxyprogesterone acetate had no significant effect on

95 py of oestrogen with cyclic progestagen (eg. medroxyprogesterone acetate) had a relative risk of 14 (

96 with or without continuous administration of medroxyprogesterone acetate has failed to slow the progr

97 nt who is amenorrheic is currently receiving medroxyprogesterone acetate; her ultimate menstrual and

98 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1380)

99 of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, in 8506 women) or placebo (

100 er estrogen/progesterone oral combination or medroxyprogesterone acetate intramuscular) contraceptive

101 rs of channel activation, we discovered that medroxyprogesterone acetate, levonorgestrel, and aldoste

102 The steroids medroxyprogesterone acetate, levonorgestrel, and aldoste

103 hich reduced total and progressive motility, medroxyprogesterone acetate, levonorgestrel, and aldoste

104 We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]

105 ), progestins and metabolites (progesterone, medroxyprogesterone acetate, megestrol acetate, mifepris

106 d equine estrogens (CEE) (0.625 mg/day) plus medroxyprogesterone acetate (MPA) (<10 mg/day) or oral C

107 affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM).

108 with 10(-8) mol/L estradiol +/- 10(-7) mol/L medroxyprogesterone acetate (MPA) +/- 1 IU/mL thrombin p

109 ltured DCs incubated with estradiol (E2) +/- medroxyprogesterone acetate (MPA) +/- thrombin.

110 d equine estrogens (CEE) 0.625 mg/d; CEE and medroxyprogesterone acetate (MPA) 10 mg on days 1 to 12

111 d equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily, in 16,60

112 jugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo.

113 Progesterone or medroxyprogesterone acetate (MPA) alone did not support

114 articipants and of these same estrogens plus medroxyprogesterone acetate (MPA) among participants wit

115 gated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA) and 8102, placebo.

116 nce of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and CEE-alone on ovari

117 Medroxyprogesterone acetate (MPA) and dydrogesterone (DD

118 ed progestin-only injectable contraceptives, medroxyprogesterone acetate (MPA) and norethisterone ace

119 n the presence of the hormonal contraceptive medroxyprogesterone acetate (MPA) and progesterone and t

120 ble with potent steroidal progestins such as medroxyprogesterone acetate (MPA) and trimegestone (TMG)

121 of three regimens of progestational agents: medroxyprogesterone acetate (MPA) at 2.5 mg daily (ie, c

122 ormation in animal models, and the progestin medroxyprogesterone acetate (MPA) blocks this effect.

123 dies indicate that the exogenous sex steroid medroxyprogesterone acetate (MPA) can impair cell-mediat

124 treated with estrogen (E2) for 2 d or E2 and medroxyprogesterone acetate (MPA) for 6 d.

125 s of conjugated equine estrogens (CEEs) with medroxyprogesterone acetate (MPA) improve vasomotor symp

126 We found that treatment with the progestin medroxyprogesterone acetate (MPA) induced the expression

127 The one major study that used oral medroxyprogesterone acetate (MPA) noted a response rate

128 It has been shown that medroxyprogesterone acetate (MPA) regresses cervical can

129 gated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA) were the only hormonal

130 We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when gi

131 ated equine estrogen (CEE) alone or CEE plus medroxyprogesterone acetate (MPA)) on global cognitive f

132 ormonal contraceptive (etonogestrel (ENG) or medroxyprogesterone acetate (MPA)).

133 is mouse model was used to determine whether medroxyprogesterone acetate (MPA), a progestin drug, is

134 ation of blood CD4+ T cells with TFV or TAF, Medroxyprogesterone acetate (MPA), but not Levonorgestre

135 ated equine estrogens (CEE), CEE plus cyclic medroxyprogesterone acetate (MPA), CEE plus daily MPA, a

136 rial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, ve

137 Medroxyprogesterone acetate (MPA), designed to mimic the

138 ining ART, participants initiated injectable medroxyprogesterone acetate (MPA), implantable etonogest

139 progesterone or three exogenous progestins (medroxyprogesterone acetate (MPA), norethindrone (NET),

140 X-GPs) treated with vehicle, estradiol (E2), medroxyprogesterone acetate (MPA), or E2+MPA.

141 We examined the effects of medroxyprogesterone acetate (MPA), the compound most com

142 of progesterone and the synthetic progestin, medroxyprogesterone acetate (MPA).

143 c E(2) and progesterone, or chronic E(2) and medroxyprogesterone acetate (MPA).

144 with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA).

145 ated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) v

146 free medium with or without the progestogen, medroxyprogesterone acetate (MPA; 10(-6) M), using inter

147 ated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) o

148 itotoxicity, whereas the synthetic progestin medroxyprogesterone acetate (MPA; Provera) is not.

149 (1) progestin (medroxyprogesterone acetate, MPA) alters neointima forma

150 in injured carotid arteries, (2) progestin (medroxyprogesterone acetate, MPA) blocks the vasoprotect

151 whereas combined estrogen plus a progestin (medroxyprogesterone acetate, MPA) HRT increases this ris

152 an 50% in parallel incubations that included medroxyprogesterone acetate (n = 12, P < 0.05).

153 conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380) or placebo (n = 1

154 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1

155 5 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380), or placebo (n =

156 of conjugated equine estrogen with 2.5 mg of medroxyprogesterone acetate (n = 2145) or matching place

157 of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (n = 2229), or a matching pl

158 vudine-based therapy and intramuscular depot medroxyprogesterone acetate (n = 25), copper intrauterin

159 conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 8506) or placebo (n = 8

160 f conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 8506) or placebo (n = 8

161 5 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate (n=8506) or matching placebo

162 udy would merit complete withdrawal of depot medroxyprogesterone acetate needs to be balanced against

163 s significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-

164 ral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate or a matching placebo.

165 In term DC cultures, E2 + medroxyprogesterone acetate or E2 + Dex enhanced FKBP51

166 facility to a long acting progestogen (depot medroxyprogesterone acetate or levonorgestrel releasing

167 ormone therapy with conjugated estrogens and medroxyprogesterone acetate or placebo and followed for

168 gen (conjugated equine oestrogens [CEE] plus medroxyprogesterone acetate) or placebo, and the other i

169 conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate, or placebo (n = 7,809), wit

170 conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, or placebo.

171 women without a uterus (n = 560) and E plus medroxyprogesterone acetate (P) for those with an intact

172 625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo.

173 Research suggests that Depo-Provera (depot medroxyprogesterone acetate; Pfizer, New York City, New

174 ease in HIV risk in the ten studies of depot medroxyprogesterone acetate (pooled hazard ratio [HR] 1.

175 Estrogen and estrogen plus medroxyprogesterone acetate produced significant reducti

176 We also report that synthetic progestin medroxyprogesterone acetate promotes regression of cance

177 estrogen, both alone and in combination with medroxyprogesterone acetate, reduced mean (+/-SD) plasma

178 strogen (estradiol, 1 mg/day) and progestin (medroxyprogesterone acetate) replacement therapy were co

179 ype of hormone used (ex. progesterone versus medroxyprogesterone acetate), the duration of the postme

180 7 days in either estradiol or estradiol plus medroxyprogesterone acetate to mimic the decidualizing s

181 ated with estradiol (E2; control) or with E2+medroxyprogesterone acetate (to mimic pregnancy)+/-throm

182 Depot medroxyprogesterone acetate use associated with increase

183 Treatment with oral conjugated estrogen plus medroxyprogesterone acetate was not associated with a si

184 gestogen contraceptives (IPCs), mostly depot medroxyprogesterone acetate, was 0.9 (95% confidence int

185 al tracts of Swiss Webster mice treated with medroxyprogesterone acetate were exposed in vivo to a 4%

186 of HIV acquisition for all women using depot medroxyprogesterone acetate, with a smaller increase in

187 5-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among wo